Biomarkers of Alzheimer's Disease Progression
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 1, 2016
app pub date -
Oct 10, 2014
filing date -
Nov 8, 2013
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided is a method for measuring the propensity of a patient to suffer progression of Alzheimer's disease that comprises, in either order: a) conducting a first immunoassay of a patient sample to determine the content (Tau-C′) of a C-terminal epitope present at the terminus of the amino acid sequence -SSTGSIDMVD (SEQ ID NO:1), and b) conducting a second immunoassay of the sample to determine the content (Tau-A′) of an N-terminal epitope present at the terminus of the amino acid sequence TPRGAAPPGQ- (SEQ ID NO:2), and c) calculating an index as a ratio Tau-A′/Tau-C′ between the second level and the first level. The method may be used to select patients for a clinical trial of an intervention in Alzheimer's disease or to evaluate a therapy.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully